Abbott India Ltd.

NSE: ABBOTINDIA BSE: 500488 SECTOR: Pharmaceuticals & Drugs  105k   924   128

21865.80
+42.75 (0.20%)
NSE: Today, 03:51 PM

Price Summary

Today's High

₹ 21989.95

Today's Low

₹ 21800.25

52 Week High

₹ 23140

52 Week Low

₹ 17325

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

46463.3 Cr.

Enterprise Value

43714.08 Cr.

No. of Shares

2.12 Cr.

P/E

48.94

P/B

14.57

Face Value

₹ 10

Div. Yield

1.49 %

Book Value (TTM)

₹  1500.54

CASH

2749.22 Cr.

DEBT

0 Cr.

Promoter Holding

74.99 %

EPS (TTM)

₹  446.8

Sales Growth

14.14%

ROE

29.95 %

ROCE

40.53%

Profit Growth

15.64 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Abbott India Ltd.

BRUFEN Digene DUPHALAC Zolfresh Cremaffin Solspre Cremalax Ganaton LIBRAX THYROCAB Eptoin OBIMET SOLFE Wymox

Index Presence

The company is present in 31 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.14%
3 Year10.17%
5 Year11.13%

Profit Growth

1 Year15.64%
3 Year21.05%
5 Year23.62%

ROE%

1 Year29.95%
3 Year28.31%
5 Year27.19%

ROCE %

1 Year40.53%
3 Year38.2%
5 Year38.62%

Debt/Equity

0

Price to Cash Flow

49.03

Interest Cover Ratio

57.5303664921466

CFO/PAT (5 Yr. Avg.)

1.00630389298829

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 74.99 0
Dec 2022 74.99 0
Sep 2022 74.99 0
Jun 2022 74.99 0
Mar 2022 74.99 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.0459759345302% for the Past 3 years.
  • Company has been maintaining healthy ROE of 28.3098826669177% over the past 3 years.
  • Company has been maintaining healthy ROCE of 38.1957806387755% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 57.5303664921466.
  • The company has an efficient Cash Conversion Cycle of -42.9917507127215 days.
  • Company has a healthy liquidity position with current ratio of 3.20235374296661.
  • The company has a good cash flow management; CFO/PAT stands at 1.00630389298829.
  • The company has a high promoter holding of 74.99%.

 Limitations

  • The company has shown a poor revenue growth of 10.1723415368759% for the Past 3 years.
  • The company is trading at a high PE of 48.94.
  • The company is trading at a high EV/EBITDA of 32.1245.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 1254.75 1304.37 1379.48 1326.48 1343.08
Total Expenditure 961.2 1033.97 1036.18 1009.99 1062.96
Operating Profit 293.55 270.4 343.3 316.49 280.12
Other Income 21.32 26.36 33.53 39.94 49.64
Interest 5.14 4.22 3.97 3.79 4.01
Depreciation 17.43 17.35 17.47 17.81 17.34
Exceptional Items 0 0 0 0 0
Profit Before Tax 292.3 275.19 355.39 334.83 308.41
Tax 80.89 69.55 89.87 88 76.99
Profit After Tax 211.41 205.64 265.52 246.83 231.42
Adjusted EPS (Rs) 99.49 96.77 124.95 116.16 108.9

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 3298.5 3678.6 4093.14 4310.02 4919.27
Total Expenditure 2775.1 3074.56 3336.96 3391.13 3831.74
Operating Profit 523.4 604.05 756.18 918.89 1087.53
Other Income 118.09 113.98 114.66 83.47 77.4
Interest 3.82 2.25 8.53 18.28 19.1
Depreciation 16.19 16.92 59.61 58.13 66.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 621.48 698.85 802.7 925.95 1079.73
Tax 220.26 248.52 209.77 235.26 281.03
Net Profit 401.22 450.33 592.93 690.69 798.7
Adjusted EPS (Rs.) 188.81 211.93 279.03 325.03 375.86

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 21.25 21.25 21.25 21.25 21.25
Total Reserves 1671.51 1987.34 2410.45 2580.91 2798.54
Borrowings 0 0 0 0 0
Other N/C liabilities 40.75 62.36 209.6 189.62 184.18
Current liabilities 668.08 856.89 891.11 1030.86 1203.19
Total Liabilities 2401.59 2927.84 3532.41 3822.64 4207.16
Assets
Net Block 81.38 104.96 269.83 250.78 271
Capital WIP 2.17 0.73 1.64 0.66 0.66
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 48.91 56.69 50.91 78.8 79.35
Other N/C Assets 38 4.47 5.38 4.99 3.11
Current Assets 2231.13 2760.98 3204.65 3487.41 3853.04
Total Assets 2401.59 2927.84 3532.41 3822.64 4207.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 621.48 698.85 802.7 925.95 1079.73
Adjustment -76.92 -77.46 -17.22 24.99 27.98
Changes in Assets & Liabilities -186.96 134.41 69.82 11.26 128.94
Tax Paid -204.9 -256.67 -229.17 -235.46 -288.99
Operating Cash Flow 152.7 499.13 626.13 726.74 947.66
Investing Cash Flow -214.84 -257 -401.21 -71.82 -395.84
Financing Cash Flow -102.43 -142.8 -216.79 -581.79 -637.38
Net Cash Flow -164.56 99.33 8.13 73.13 -85.56

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 74.99 74.99 74.99 74.99 74.99
abbott capital ind... 50.44 50.44 50.44 50.44 50.44
abbott healthcare ... 17.62 17.62 17.62 17.62 17.62
british colloids l... 6.92 6.92 6.92 6.92 6.92
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 25.01 25.01 25.01 25.01 25.01
life insurance cor... 2.10 2.10 1.07 - -
canara robeco mutu... - - - 1.49 -
canara robeco mutu... - - - - 1.36
canara robeco mutu... - - 1.29 - -
canara robeco mutu... - 1.12 - - -
sbi arbitrage oppo... - - - 1.07 1.12
investor education... - - 0.47 0.47 0.46

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Abbott India - Quaterly Results19 May 2023, 4:03PM Abbott India - Quaterly Results19 May 2023, 4:03PM Abbott India - Quaterly Results19 May 2023, 4:03PM Abbott India informs about issuance of duplicate share certificate19 May 2023, 11:10AM Abbott India informs about non-applicability of large corporate entity 17 Apr 2023, 12:03PM Abbott India informs about details of loss of certificate1 Mar 2023, 5:19PM Abbott India - Quaterly Results10 Feb 2023, 2:01PM Abbott India - Quaterly Results10 Feb 2023, 2:01PM Abbott India - Quaterly Results10 Feb 2023, 2:01PM Abbott India informs about disclosure of related party transactions25 Nov 2022, 5:18PM Abbott India informs about issuance of duplicate share certificate 16 Nov 2022, 5:12PM Abbott India informs about press release15 Nov 2022, 12:15PM Abbott India - Quaterly Results14 Nov 2022, 1:17PM Abbott India - Quaterly Results14 Nov 2022, 1:17PM Abbott India - Quaterly Results14 Nov 2022, 1:17PM Abbott India informs about issuance of duplicate share certificates21 Oct 2022, 12:38PM Abbott India informs about issuance of duplicate share certificate20 Oct 2022, 12:32PM Abbott India informs about loss of share certificates19 Oct 2022, 11:49AM Abbott India informs about press release11 Oct 2022, 4:58PM Abbott India informs about analyst meet26 Sep 2022, 5:10PM Abbott India informs about voting results 11 Aug 2022, 12:19PM Abbott India - Quaterly Results10 Aug 2022, 5:39PM Abbott India - Quaterly Results10 Aug 2022, 5:39PM Abbott India reports 39% rise in Q4 net profit18 May 2022, 12:08PM Abbott India - Quaterly Results17 May 2022, 2:32PM Abbott India - Quaterly Results17 May 2022, 2:32PM Abbott India - Quaterly Results17 May 2022, 2:32PM Abbott India informs about issuance of duplicate share certificates27 Apr 2022, 4:44PM Abbott India informs about issuance of duplicate share certificate27 Apr 2022, 10:03AM Abbott India informs about issuance of duplicate share certificate26 Apr 2022, 9:36AM Abbott launches Arachitol Gummies in India11 Apr 2022, 4:58PM Abbott India informs about unaudited financial results9 Feb 2022, 3:45PM Abbott India - Quaterly Results9 Feb 2022, 2:11PM Abbott India - Quaterly Results9 Feb 2022, 2:11PM Abbott India - Quaterly Results9 Feb 2022, 2:11PM Abbott India informs about certificate7 Jan 2022, 4:08PM Abbott India informs about closure of trading window30 Dec 2021, 3:21PM Abbott India informs about issuance of duplicate share certificate 7 Dec 2021, 4:17PM Abbott India informs about issuance of duplicate share certificates3 Dec 2021, 12:58PM Abbott India informs about certificate6 Oct 2021, 10:42AM Abbott introduces single-dose formulation of carbetocin in India31 Aug 2021, 3:15PM Abbott launches COVID-19 home test kit in India12 Jul 2021, 3:34PM Abbott India informs about newspaper advertisement3 Jul 2021, 3:29PM Abbott India informs about analyst meet29 Jun 2021, 12:55PM Abbott launches medical device to treat congenital heart defects in premature infants16 Jun 2021, 12:32PM Abbott India informs about press release19 May 2021, 3:30PM Abbott India informs about newspaper publication10 May 2021, 11:11AM Abbott India informs about board meeting10 May 2021, 11:09AM Abbott India informs about non-applicability of large corporate entity9 Apr 2021, 10:59AM Abbott India informs about board meeting2 Nov 2020, 10:41AM

Abbott India Stock Price Analysis and Quick Research Report. Is Abbott India an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Abbott India and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 947.66 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Abbott India has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Abbott India , the EPS growth was 15.6379737784689 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Abbott India has OPM of 22.1075484777213 % which is a good sign for profitability.
     
  • ROE: Abbott India have a healthy ROE of 29.950201742939 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Abbott India

X